Search Results

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

• Authors : Garvey, W Timothy (AUTHOR); Frias, Juan P (AUTHOR); Jastreboff, Ania M (AUTHOR)

Subjects: ELI Lilly & Co.; TYPE 2 diabetes; CLINICAL trials

• Source: Lancet. Aug2023, Vol. 402 Issue 10402, p613-626. 14p.

Record details

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.

• Authors : Rosenstock, Julio (AUTHOR); Frias, Juan (AUTHOR); Jastreboff, Ania M (AUTHOR)

Subjects: ELI Lilly & Co.; GLUCAGON receptors; TYPE 2 diabetes

• Source: Lancet. Aug2023, Vol. 402 Issue 10401, p529-544. 16p.

Record details

Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.

• Authors : Ramanan, Athimalaipet V (AUTHOR); Quartier, Pierre (AUTHOR); Okamoto, Nami (AUTHOR)

Subjects: ELI Lilly & Co.; JUVENILE idiopathic arthritis; BARICITINIB

• Source: Lancet. Aug2023, Vol. 402 Issue 10401, p555-570. 16p.

Record details

Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.

• Authors : Frias, Juan P (AUTHOR); Hsia, Stanley (AUTHOR); Eyde, Sarah (AUTHOR)

Subjects: TYPE 2 diabetes; ELI Lilly & Co.; WATER restrictionsSLOVAKIA; POLAND; HUNGARY

• Source: Lancet. 8/5/2023, Vol. 402 Issue 10400, p472-483. 12p.

Record details

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).

• Authors : Morand, Eric F (AUTHOR); Vital, Edward M (AUTHOR); Petri, Michelle (AUTHOR)

Subjects: ELI Lilly & Co.; SYSTEMIC lupus erythematosus; CLINICAL trials

• Source: Lancet. Mar2023, Vol. 401 Issue 10381, p1001-1010. 10p.

Record details

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).

• Authors : Petri, Michelle (AUTHOR); Bruce, Ian N (AUTHOR); Dörner, Thomas (AUTHOR)

Subjects: ELI Lilly & Co.; SYSTEMIC lupus erythematosus; CLINICAL trials

• Source: Lancet. Mar2023, Vol. 401 Issue 10381, p1011-1019. 9p.

Record details

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.

• Authors : Del Prato, Stefano (AUTHOR); Kahn, Steven E (AUTHOR); Pavo, Imre (AUTHOR)

Subjects: TYPE 2 diabetes; ELI Lilly & Co.; CARDIOVASCULAR diseases risk factors

• Source: Lancet. Nov2021, Vol. 398 Issue 10313, p1811-1824. 14p.

Record details

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.

• Authors : Ludvik, Bernhard (AUTHOR); Giorgino, Francesco (AUTHOR); Jódar, Esteban (AUTHOR)

Subjects: INSULIN aspart; ELI Lilly & Co.; SODIUM-glucose cotransporter 2 inhibitors

• Source: Lancet. Aug2021, Vol. 398 Issue 10300, p583-598. 16p.

Record details

Lilly's misleading promotion.

• Authors : Ahmad, Syed Rizwanuddi

Subjects: ELI Lilly & Co. ELI Lilly & Co. ELI Lilly & Co. LLY; UNITED States. Food & Drug Administration

• Source: Lancet. 8/13/1994, Vol. 344 Issue 8920, p464. 2p.

Record details

Unsolicited fluoxetine mailing triggers investigation in USA.

Subjects: FLUOXETINE; ELI Lilly & Co.; MEDICAL ethics

• Source: Lancet. 7/20/2002, Vol. 360 Issue 9328, p234. 1p. 1 Color Photograph.

Record details